Eccogene announced Michael R. Wiley, Ph.D. joined Scientific Advisory Board



 Shanghai, China, May 21, 2020 –Eccogene, Inc., a research driven biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced today the addition of Michael R. Wiley, Ph.D., to its scientific advisory board.

Dr. Wiley earned his PhD in chemistry from University of Utah and finished postdoctoral training at Columbia University. He is a well-recognized drug discovery leader with 30 years of experience in the pharmaceutical industry. Most recently, he was Research Fellow at Eli Lilly and company. He has been a successful scientific leader to deliver multiple clinical candidates across diverse therapeutic areas. His expertise spans a wide range of target families, biochemical pathways, chemotypes and mechanisms of action. In addition, Dr. Wiley is also appreciated for his passion of sharing, coaching and mentoring people in the industry across diverse disciplines, cultures and geographies.

“We are privileged to welcome Dr. Wiley to join our scientific advisory board,” said Jingye Zhou, PhD, CEO of Eccogene. “Dr. Wiley’s outstanding drug hunting capabilities, as well as his experiences in career development and project management will certainly be very helpful for our young team.”